InBody Co.Ltd (041830)
KOSDAQ · Korea · prices in KRW · close of 23 Oct 2026
Key indicators
| Last close | KRW 47,050.00 |
|---|---|
| 52-week range | 26,200.00 – 73,500.00 |
| Return, 1 month / 3 months | −11.6% / −4.2% |
| Return, 1 year / 3 years | +74.4% / +124.9% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 34 |
| Volatility (1 year) | 66.8% |
| Worst drawdown (1 year) | -33.5% |
| Average daily value traded | 5,871.83M KRW |
| Dividend yield | 1.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
InBody Co.Ltd develops and manufactures body composition analysis equipment that uses bioelectrical impedance to estimate muscle, fat and water in the human body. Its devices are used by hospitals, clinics, fitness centres and wellness providers for assessing body composition and tracking physical condition. The company is based in South Korea, where its products are made and from where they are supplied to customers in many countries.
InBody Co.Ltd trades under the code 041830 on the KOSDAQ in Korea, with its price quoted in South Korean won (KRW). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
InBody Co.Ltd (041830) trades on the KOSDAQ in Korea. It last closed at KRW 47,050.00 on 23 October 2026.
Its price-based Market X-Ray is 77 out of 100 (a strong price profile), ranking 72 of 1,832 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 74.4% and over the last three months it fell 4.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on KOSDAQ
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 88 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 9.7% | ||
| From 52-week high | -33.5% | ||
| Momentum | 80 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | -4.2% | ||
| 6-month return | 60.3% | ||
| 12-month return, skipping the last month | 97.2% | ||
| Stability (higher is calmer) | 68 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 66.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -33.5% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 5,871.83M KRW | ||
| Zero-volume days | 0.0% | ||
| Income | 44 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.3% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | −10.0% |
|---|---|
| 1 month | −11.6% |
| 3 months | −4.2% |
| 6 months | +60.3% |
| 1 year | +74.4% |
| 3 years | +124.9% |
| 5 years | +84.7% |
Signals
| 50-day / 200-day average | 57,070.00 / 42,893.59 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2,772.73 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Mar 2026 | KRW 600.0000 |
| 28 Mar 2025 | KRW 400.0000 |
| 27 Dec 2023 | KRW 350.0000 |
| 28 Dec 2022 | KRW 300.0000 |
| 29 Dec 2021 | KRW 200.0000 |
| 29 Dec 2020 | KRW 140.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on KOSDAQ; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.